Advanced in Histiocytosis

Dr. Katherine A. Janeway

Pediatric Hematology Oncology

Dana Farber Cancer Institute, 44 Binney Street,

Boston, MA

Advanced in Histiocytosis

Dana Farber Cancer Institute, 44 Binney Street,

Boston, MA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Katherine Janeway is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Janeway is rated as an Advanced provider by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Neuroblastoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 175 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 11 clinical trials in the study of Histiocytosis.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatrics in MA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Anthem

Blue Cross Blue Shield

BMC HealthNet

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE SNP

Humana

HMO
INDEMNITY
POS
PPO

Medicaid

OTHER MEDICAID
STATE MEDICAID

Neighborhood

MANAGED MEDICAID PLAN
MEDICARE ASSISTANCE PROGRAM
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL

View 1 Less Insurance Carrier -

Locations

Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115

Call: 617-632-4994

Additional Areas of Focus

Dr. Janeway has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Radiation, Drug, Biological, Other

Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Nirogacestat

Study Phase: Phase 2

Phase II Trial of Olaparib in Combination With Ceralasertib in Patients With Recurrent Osteosarcoma

Enrollment Status: Active_not_recruiting

Publish Date: July 18, 2025

Intervention Type: Drug

Study Drugs: Olaparib, Ceralasertib

Study Phase: Phase 2

A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma

Enrollment Status: Suspended

Publish Date: July 18, 2025

Intervention Type: Biological, Procedure

Study Drug: Trastuzumab Deruxtecan

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: July 09, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

Multicenter Cohort Study To Evaluate Outcomes After Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults With Solid Tumors: The iCat2, GAIN Consortium Study

Enrollment Status: Active_not_recruiting

Publish Date: March 06, 2025

Intervention Type: Genetic

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

Enrollment Status: Completed

Publish Date: November 01, 2024

Intervention Type: Other, Drug

Study Drug: Palbociclib

Study Phase: Phase 2

Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Enrollment Status: Completed

Publish Date: January 22, 2024

Intervention Type: Biological, Other

Study Drug: Denosumab

Study Phase: Phase 2

A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma

Enrollment Status: Completed

Publish Date: October 26, 2023

Intervention Type: Other, Biological

Study Drugs: Dinutuximab, Sargramostim

Study Phase: Phase 2

A Phase II Study of M6620 (VX-970) in Selected Solid Tumors

Enrollment Status: Completed

Publish Date: July 07, 2023

Intervention Type: Drug

Study Drug: M6620

Study Phase: Phase 2

A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; NSC# 763737), in Recurrent or Refractory Osteosarcoma

Enrollment Status: Completed

Publish Date: January 18, 2022

Intervention Type: Other, Drug

Study Drug: Glembatumumab Vedotin

Study Phase: Phase 2

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Enrollment Status: Terminated

Publish Date: April 30, 2021

Intervention Type: Radiation

Study Phase: Phase 1/Phase 2

View 19 Less Clinical Trials

175 Total Publications

Supporting Participant Engagement in Cancer Genomics Research in Rare Cancers: A Qualitative Study of Patients, Caregivers, and Advocates.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: July 28, 2025

View All 175 Publications

Similar Doctors

Distinguished in Histiocytosis

Dr. Barbara A. Degar

Pediatric Hematology Oncology

Distinguished in Histiocytosis

Dr. Barbara A. Degar

Pediatric Hematology Oncology

44 Binney St, Jimmy Fund Clinic,

Boston, MA

(0.1 miles away)

617-632-6801

Languages Spoken:

English

See accepted insurances

Barbara Degar is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Degar is rated as a Distinguished provider by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Histiocytosis, and Reticulohistiocytoma.

Advanced in Histiocytosis

Dr. Christine N. Duncan

Pediatric Hematology Oncology

Advanced in Histiocytosis

Dr. Christine N. Duncan

Pediatric Hematology Oncology

44 Binney St, Jfc,

Boston, MA

(0.1 miles away)

617-632-6255

Languages Spoken:

English

See accepted insurances

Christine Duncan is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Duncan is rated as a Distinguished provider by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Adrenoleukodystrophy (ALD), Hepatic Venoocclusive Disease with Immunodeficiency, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Tissue Biopsy.

Advanced in Histiocytosis

Dr. Leslie E. Lehmann

Pediatric Hematology Oncology

Advanced in Histiocytosis

Dr. Leslie E. Lehmann

Pediatric Hematology Oncology

44 Binney St, Dana Farber Cancer Institute,

Boston, MA

(0.1 miles away)

617-632-4923

Languages Spoken:

English

See accepted insurances

Leslie Lehmann is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Lehmann is rated as a Distinguished provider by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Hepatic Venoocclusive Disease with Immunodeficiency, Dyskeratosis Congenita, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Tissue Biopsy.

VIEW MORE HISTIOCYTOSIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Janeway's expertise for a condition

ConditionClose